Jonathan C Fox has bought stock on 2 days since Dec 2023

Jonathan C. Fox, M.D., Ph.D., FACC is a biopharmaceutical executive and physician–scientist who serves as a director of Edgewise Therapeutics, Inc. (NASDAQ: EWTX), where he sits on the board of directors as a corporate insider.( He is also the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biotechnology company focused on genetically targeted therapies.( Dr. Fox has recently reported insider transactions in Edgewise Therapeutics stock, including open-market purchases and compensation-related option grants, reflecting his ongoing role as a board member.(

Earlier in his career, Fox served as chief medical officer of MyoKardia, Inc. from 2013 to 2016 and then as a senior advisor from 2016 to 2017, following prior senior R&D roles at SmithKline Beecham, Merck Research Laboratories, and AstraZeneca.( He has also worked as a consultant at Nigel-Montgomery, LLC, and has held academic positions, including faculty service at the University of Pennsylvania School of Medicine and an adjunct professorship at the Stanford University Cardiovascular Institute.( Fox sits on the board of ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research.( He earned an A.B. in biology, a Ph.D. in experimental pathology, and an M.D. from the University of Chicago, completed training in Internal Medicine and Cardiology at Duke University, and is ABIM-certified in Cardiovascular Diseases as well as a Fellow of the American College of Cardiology.(

Written by Perplexity from public sources.